Acquisitions - Schedule of Components and Fair Value Allocation of the Consideration Transferred in Connection with Acquisitions (Details) € in Millions, £ in Millions, SFr in Millions, $ in Millions								3 Months Ended	12 Months Ended
	Oct. 02, 2023 USD ($)	Jan. 03, 2023 USD ($)	Jan. 03, 2023 CHF (SFr)	Apr. 01, 2022 USD ($)	Apr. 01, 2022 GBP (£)	Jan. 18, 2022 USD ($)	Jan. 18, 2022 EUR (€)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Consideration Transferred:
Fair value of redeemable noncontrolling interest - other shareholders									$ 0.0	$ 0.0	$ 0.0
Total consideration transferred									44.7	26.8
Allocation of Consideration Transferred:
Goodwill									582.6	457.6	339.5	$ 320.4
Bargain purchase gain									144.1	0.0	0.0
BSI Nano
Allocation of Consideration Transferred:
Goodwill									294.3	292.1	$ 238.9	$ 228.0
Biognosys, Ag
Consideration Transferred:
Fair value of contingent consideration		$ 6.3	SFr 5.9					$ 6.3
Total consideration transferred | SFr			SFr 75.0
Biognosys, Ag | Bruker CALID
Consideration Transferred:
Total cash consideration									73.6
Cash acquired									(9.5)
Holdback									0.2
Fair value of hybrid financial instruments - founders									0.0
Fair value of redeemable noncontrolling interest - other shareholders									2.5
Fair value of contingent consideration									0.0
Total consideration transferred									66.8
Allocation of Consideration Transferred:
Accounts receivable									3.6
Inventories									0.4
Other current assets									0.9
Property, plant and equipment									8.0
Other assets									4.3
Goodwill									47.5
Liabilities assumed									(25.4)
Total consideration allocated									66.8
Biognosys, Ag | Bruker CALID | Technology
Allocation of Consideration Transferred:
Intangible assets									10.2
Biognosys, Ag | Bruker CALID | Customer relationships
Allocation of Consideration Transferred:
Intangible assets									13.8
Biognosys, Ag | Bruker CALID | Backlog
Allocation of Consideration Transferred:
Intangible assets									0.8
Biognosys, Ag | Bruker CALID | Trade name
Allocation of Consideration Transferred:
Intangible assets									2.7
Zontal Inc | Bruker BioSpin
Consideration Transferred:
Total cash consideration									14.8
Cash acquired									(0.3)
Holdback									0.0
Fair value of hybrid financial instruments - founders									18.5
Fair value of redeemable noncontrolling interest - other shareholders									0.0
Fair value of contingent consideration									0.5
Total consideration transferred									33.5
Allocation of Consideration Transferred:
Accounts receivable									0.7
Inventories									0.0
Other current assets									0.3
Property, plant and equipment									0.0
Other assets									2.5
Goodwill									25.9
Liabilities assumed									(7.0)
Total consideration allocated									33.5
Zontal Inc | Bruker BioSpin | Technology
Allocation of Consideration Transferred:
Intangible assets									5.8
Zontal Inc | Bruker BioSpin | Customer relationships
Allocation of Consideration Transferred:
Intangible assets									4.0
Zontal Inc | Bruker BioSpin | Backlog
Allocation of Consideration Transferred:
Intangible assets									0.2
Zontal Inc | Bruker BioSpin | Trade name
Allocation of Consideration Transferred:
Intangible assets									1.1
MIRO Analytical AG | Bruker CALID
Consideration Transferred:
Total cash consideration									8.6
Cash acquired									(0.5)
Holdback									1.0
Fair value of hybrid financial instruments - founders									9.3
Fair value of redeemable noncontrolling interest - other shareholders									0.5
Fair value of contingent consideration									0.0
Total consideration transferred									18.9
Allocation of Consideration Transferred:
Accounts receivable									0.0
Inventories									0.8
Other current assets									0.0
Property, plant and equipment									0.1
Other assets									0.0
Goodwill									11.1
Liabilities assumed									(2.5)
Total consideration allocated									18.9
MIRO Analytical AG | Bruker CALID | Technology
Allocation of Consideration Transferred:
Intangible assets									8.9
MIRO Analytical AG | Bruker CALID | Customer relationships
Allocation of Consideration Transferred:
Intangible assets									0.3
MIRO Analytical AG | Bruker CALID | Backlog
Allocation of Consideration Transferred:
Intangible assets									0.0
MIRO Analytical AG | Bruker CALID | Trade name
Allocation of Consideration Transferred:
Intangible assets									0.2
PreOmics GmbH
Consideration Transferred:
Total consideration transferred						$ 52.1	€ 46.1
PreOmics GmbH | Bruker CALID
Consideration Transferred:
Total cash consideration										52.1
Cash acquired										(16.0)
Fair value of hybrid financial instruments - founders										20.9
Fair value of redeemable noncontrolling interest - other shareholders										6.8
Fair value of contingent consideration										0.0
Working capital adjustment										0.0
Total consideration transferred										63.8
Allocation of Consideration Transferred:
Accounts receivable										0.4
Inventories										0.6
Other current assets										0.7
Property, plant and equipment										1.3
Other assets										0.4
Goodwill										47.0
Liabilities assumed										(7.9)
Total consideration allocated										63.8
PreOmics GmbH | Bruker CALID | Technology
Allocation of Consideration Transferred:
Intangible assets										12.5
PreOmics GmbH | Bruker CALID | Customer relationships
Allocation of Consideration Transferred:
Intangible assets										6.9
PreOmics GmbH | Bruker CALID | Backlog
Allocation of Consideration Transferred:
Intangible assets										0.0
PreOmics GmbH | Bruker CALID | Trade name
Allocation of Consideration Transferred:
Intangible assets										1.9
Optimal
Consideration Transferred:
Fair value of contingent consideration				$ 0.4	£ 0.3
Optimal | Bruker BioSpin
Consideration Transferred:
Total cash consideration										40.3
Cash acquired										(6.2)
Fair value of hybrid financial instruments - founders										0.0
Fair value of redeemable noncontrolling interest - other shareholders										0.0
Fair value of contingent consideration										0.4
Working capital adjustment										0.0
Total consideration transferred										34.5
Allocation of Consideration Transferred:
Accounts receivable										1.9
Inventories										0.0
Other current assets										0.8
Property, plant and equipment										0.1
Other assets										0.8
Goodwill										18.6
Liabilities assumed										(8.8)
Total consideration allocated										34.5
Optimal | Bruker BioSpin | Technology
Allocation of Consideration Transferred:
Intangible assets										5.9
Optimal | Bruker BioSpin | Customer relationships
Allocation of Consideration Transferred:
Intangible assets										12.9
Optimal | Bruker BioSpin | Backlog
Allocation of Consideration Transferred:
Intangible assets										1.1
Optimal | Bruker BioSpin | Trade name
Allocation of Consideration Transferred:
Intangible assets										1.2
Inscopix Inc | BSI Nano
Consideration Transferred:
Total cash consideration										101.5
Cash acquired										(12.1)
Fair value of hybrid financial instruments - founders										0.0
Fair value of redeemable noncontrolling interest - other shareholders										0.0
Fair value of contingent consideration										0.0
Working capital adjustment										0.6
Total consideration transferred										90.0
Allocation of Consideration Transferred:
Accounts receivable										3.2
Inventories										2.5
Other current assets										0.9
Property, plant and equipment										0.5
Other assets										4.7
Goodwill										52.2
Liabilities assumed										(24.6)
Total consideration allocated										90.0
Inscopix Inc | BSI Nano | Technology
Allocation of Consideration Transferred:
Intangible assets										26.6
Inscopix Inc | BSI Nano | Customer relationships
Allocation of Consideration Transferred:
Intangible assets										20.8
Inscopix Inc | BSI Nano | Backlog
Allocation of Consideration Transferred:
Intangible assets										0.0
Inscopix Inc | BSI Nano | Trade name
Allocation of Consideration Transferred:
Intangible assets										$ 3.2
PhenomeX, Inc.
Consideration Transferred:
Total cash consideration	$ 121.2
Cash acquired	11.8
Fair value of contingent consideration	8.0
Total consideration transferred	109.4
Allocation of Consideration Transferred:
Bargain purchase gain									$ 144.1
PhenomeX, Inc. | BSI Nano
Consideration Transferred:
Total cash consideration	121.2
Cash acquired	(11.8)
Total consideration transferred	109.4
Allocation of Consideration Transferred:
Accounts receivable	5.6
Inventories	42.1
Other current assets	7.6
Property, plant and equipment	33.5
Deferred tax assets	182.7
Other assets	24.3
Liabilities assumed	(74.3)
Total consideration allocated	253.5
Bargain purchase gain	144.1
PhenomeX, Inc. | BSI Nano | Technology
Allocation of Consideration Transferred:
Intangible assets	24.0
PhenomeX, Inc. | BSI Nano | Customer relationships
Allocation of Consideration Transferred:
Intangible assets	$ 8.0